Drug Res (Stuttg) 2013; 63(06): 326-330
DOI: 10.1055/s-0033-1341425
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Evaluation of in vitro Dissolution and in vivo Oral Absorption of Dutasteride-loaded Eudragit E Nanoparticles

M.-S. Kim
1   Department of Pharmaceutical Engineering, Inje University, Gimhae, Korea
› Institutsangaben
Weitere Informationen


received 28. Januar 2013

accepted 27. Februar 2013

22. März 2013 (online)


The present study sought to evaluate the pharmacokinetics of dutasteride-loaded Eudragit E nanoparticle in rats. In addition, the study investigated the effect of increasing drug load on the in vitro solubility and dissolution behavior of dutasteride together with its in vivo oral absorption characteristics. The suspension of dutasteride-loaded Eudragit E nanoparticles prepared by the nanoprecipitation method showed blue opalescence and the particles were uniform in appearance. The entrapment efficiency and the mean particle size of these nanoparticles were in the range of 98.1–99.3% and 120.5–128.4 nm, respectively, and no significant difference in these parameters was observed between the nanoparticles in the sample. Eudragit E nanoparticles containing a drug load of 5% showed an increase in bioavailability by 550% as compared to dutasteride suspension. This finding is attributable to enhanced solubility and dissolution of dutasteride when formulated as nanoparticles. Furthermore, the oral absorption of dutasteride in rats increased as a function of the extent of supersaturation of dutasteride in Eudragit E nanoparticles. Therefore, the preliminary results from our study suggest that dutasteride-loaded Eudragit E nanoparticles may have significant potential for clinical application.

  • References

  • 1 Naahidi S, Jafari M, Edalat F et al. Biocompatibility of engineered nanoparticles for drug delivery. J Control Release DOI: 10.1016/j.jconrel.2012.12.013.
  • 2 Wang XQ, Zhang Q. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur J Pharm Biopharm 2012; 82: 219-229
  • 3 Jung JY, Yoo SD, Lee SH et al. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm 1999; 187: 209-218
  • 4 Qi S, Gryczke A, Belton P et al. Characterisation of solid dispersions of paracetamol and EUDRAGIT E prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis. Int J Pharm 2008; 354: 158-167
  • 5 Yoshida T, Kurimoto I, Yoshihara K et al. Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: Evaluation of solid dispersion formulations. Int J Pharm 2012; 428: 18-24
  • 6 Chellampillai B, Pawar AP. Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. Eur J Drug Metab Pharmacokinet 2011; 35: 123-129
  • 7 Dai J, Nagai T, Wang X et al. pH-sensitive nanoparticles for improving the oral bioavailability of cyclosporine. A Int J Pharm 2004; 280: 229-240
  • 8 Tang J, Xu N, Ji H et al. Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment. Int J Nanomedicine 2011; 6: 2429-2435
  • 9 Khachane P, Date AA, Nagarsenker MS. et al. nanoparticles: application in improving therapeutic efficacy and reducing ulcerogenicity of meloxicam on oral administration. J Biomed Nanotechnol 2011; 7: 590-597
  • 10 Wu TH, Yen FL, Lin LT et al. Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles. Int J Pharm 2008; 346: 160-168
  • 11 Gisleskog PO, Hermann D, Hammarlund-Udenaes M et al. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol 1999; 47: 53-58
  • 12 Evans HC, Goa KL. Dutasteride. Drugs Aging 2003; 20: 905-916
  • 13 U.S. Food Drug Administration “Application Number: 21-319.”: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen_biopharmr_P1.pdf , cited 28 Jan, 2013
  • 14 Beak IH, Kim MS. Improved supersaturation and oral absorption of dutasteride by amorphous solid dispersions. Chem Pharm Bull 2012; 60: 1468-1473
  • 15 Choo GH, Park SJ, Hwang SJ et al. Formulation and in vivo evaluation of a self-microemulsifying drug delivery system of dutasteride. Drug Research 2013; Accepted for publication
  • 16 Park SJ, Choo GH, Hwang SJ et al. Quality by Design: Screening of Critical Variables and Formulation Optimization of Eudragit E Nanoparticles Containing Dutasteride. Arch Pharm Res. 2013 DOI: http://dx.doi.org/10.1007/s12272-013-0064-z
  • 17 Kojima T, Higashi K, Suzuki T et al. Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with EUDRAGIT(®) EPO. Pharm Res 2012; 29: 2777-2791
  • 18 Wen H, Morris KR, Park K. Hydrogen bonding interactions between adsorbed polymer molecules and crystal surface of acetaminophen. J Colloid Interface Sci 2005; 290: 325-335
  • 19 Overhoff KA, McConville JT, Yang W et al. Effect of stabilizer on the maximum degree and extent of supersaturation and oral absorption of tacrolimus made by ultra-rapid freezing. Pharm Res 2008; 25: 167-175
  • 20 Ilevbare GA, Liu H, Edgar KJ et al. Understanding polymer properties important for crystal growth inhibition – Impact of chemically diverse polymers on solution crystal growth of ritonavir. Cryst Growth Des 2012; 12: 3133-3143
  • 21 Kim MS, Jin SJ, Kim JS et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm 2008; 69: 454-465
  • 22 Kim MS, Kim JS, Park HJ et al. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine 2011; 6: 2997-3009
  • 23 Janssens S, De Zeure A, Paudel A et al. Influence of preparation methods on solid state supersaturation of amorphous solid dispersions: a case study with itraconazole and eudragit e100. Pharm Res 2010; 27: 775-785
  • 24 Shim JB, Kim MJ, Kim SJ et al. Dissolution properties of control released solid dispersion of carvedilol with HPMC and Eudragit RS. J Pharm Invest 2012; 42: 285-291